Matinas BioPharma Holdings (MTNB) Cash from Financing Activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Cash from Financing Activities of $58000.0 for Q4 2025, up 5900.0% year-over-year from $966.67 in Q4 2024, and down 9.38% quarter-over-quarter from $64000.0 in Q3 2025.
Matinas BioPharma Holdings (MTNB) Cash from Financing Activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Cash from Financing Activities for 12 consecutive years, with $58000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 5900.0% year-over-year to $58000.0; the TTM figure through Dec 2025 stood at $3.4 million (down 63.04% YoY), while the FY2025 annual figure was $3.4 million, down 63.04% from the prior year.
- Cash from Financing Activities eased to $58000.0 in Q4 2025 per MTNB's latest filing, from $64000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $9.2 million in Q2 2024 and bottomed at -$67000.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $980100.0 across 5 years, with a median of $3665.0 in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 919000.0% in 2024 and fell as far as 6600.0% in 2024.
- Matinas BioPharma Holdings' Cash from Financing Activities stood at $8330.0 in 2021, then sank by 160.02% to -$5000.0 in 2022, then soared by 80.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then soared by 5900.0% to $58000.0 in 2025.
- Business Quant data shows MTNB's Cash from Financing Activities at $58000.0 in Q4 2025, $64000.0 in Q3 2025, and $1.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Jun 30, 2024 | 9.19 Mn |
| Jun 30, 2024 | 9.19 Mn |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |